BNP Paribas Financial Markets’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.16M | Sell |
31,191
-144,597
| -82% | -$4.67M | ﹤0.01% | 3214 |
|
|
2026
Q1 | $5.58M | Sell |
175,788
-54,874
| -24% | -$1.5M | ﹤0.01% | 1938 |
|
|
2025
Q4 | $6.26M | Buy |
230,662
+96,779
| +72% | +$2.55M | ﹤0.01% | 1894 |
|
|
2025
Q3 | $3.46M | Sell |
133,883
-77,377
| -37% | -$1.79M | ﹤0.01% | 2228 |
|
|
2025
Q2 | $4.3M | Buy |
211,260
+106,120
| +101% | +$2.07M | ﹤0.01% | 1954 |
|
|
2025
Q1 | $1.91M | Buy |
105,140
+42,509
| +68% | +$950K | ﹤0.01% | 2392 |
|
|
2024
Q4 | $1.58M | Buy |
62,631
+34,450
| +122% | +$936K | ﹤0.01% | 2514 |
|
|
2024
Q3 | $958K | Buy |
28,181
+21,013
| +293% | +$801K | ﹤0.01% | 2524 |
|
|
2024
Q2 | $265K | Sell |
7,168
-48,876
| -87% | -$1.84M | ﹤0.01% | 2989 |
|
|
2024
Q1 | $2.35M | Sell |
56,044
-80,557
| -59% | -$3.31M | ﹤0.01% | 1967 |
|
|
2023
Q4 | $5.42M | Buy |
136,601
+44,878
| +49% | +$1.32M | 0.01% | 1352 |
|
|
2023
Q3 | $2.52M | Buy |
91,723
+40,966
| +81% | +$1.28M | ﹤0.01% | 1724 |
|
|
2023
Q2 | $1.72M | Sell |
50,757
-40,826
| -45% | -$1.38M | ﹤0.01% | 1846 |
|
|
2023
Q1 | $3.3M | Buy |
91,583
+55,721
| +155% | +$2.4M | ﹤0.01% | 1502 |
|
|
2022
Q4 | $1.6M | Sell |
35,862
-38,909
| -52% | -$1.39M | ﹤0.01% | 1893 |
|
|
2022
Q3 | $2.1M | Buy |
74,771
+64,865
| +655% | +$1.99M | ﹤0.01% | 1929 |
|
|
2022
Q2 | $267K | Buy |
9,906
+6,125
| +162% | +$178K | ﹤0.01% | 2965 |
|
|
2022
Q1 | $129K | Sell |
3,781
-10,809
| -74% | -$346K | ﹤0.01% | 3281 |
|
|
2021
Q4 | $564K | Buy |
14,590
+5,970
| +69% | +$260K | ﹤0.01% | 2949 |
|
|
2021
Q3 | $465K | Buy |
8,620
+7,110
| +471% | +$334K | ﹤0.01% | 2780 |
|
|
2021
Q2 | $50.5K | Buy |
1,510
+1,189
| +370% | +$32.6K | ﹤0.01% | 3261 |
|
|
2021
Q1 | $6.61K | Buy |
321
+318
| +10,600% | +$7.3K | ﹤0.01% | 3855 |
|
|
2020
Q4 | $53 | Hold |
3
| – | – | ﹤0.01% | 4084 |
|
|
2020
Q3 | $44 | Hold |
3
| – | – | ﹤0.01% | 4144 |
|
|
2020
Q2 | $39 | Sell |
3
-21
| -88% | -$93 | ﹤0.01% | 4236 |
|
|
2020
Q1 | $40 | Hold |
24
| – | – | ﹤0.01% | 4246 |
|
|
2019
Q4 | $54 | Sell |
24
-232
| -91% | -$538 | ﹤0.01% | 4359 |
|
|
2019
Q3 | $545 | Sell |
256
-18
| -7% | -$42 | ﹤0.01% | 4418 |
|
|
2019
Q2 | $734 | Buy |
+274
| New | +$931 | ﹤0.01% | 4383 |
|
|
2019
Q1 | – | Sell |
-255
| Closed | -$756 | – | 4299 |
|
|
2018
Q4 | $756 | Buy |
255
+74
| +41% | +$363 | ﹤0.01% | 3958 |
|
|
2018
Q3 | $1.23K | Hold |
181
| – | – | ﹤0.01% | 4306 |
|
|
2018
Q2 | $1.37K | Sell |
181
-1,709
| -90% | -$22.8K | ﹤0.01% | 4281 |
|
|
2018
Q1 | $66.1K | Sell |
1,890
-62
| -3% | -$2.4K | ﹤0.01% | 3402 |
|
|
2017
Q4 | $83.1K | Buy |
1,952
+866
| +80% | +$37.1K | ﹤0.01% | 3400 |
|
|
2017
Q3 | $46.6K | Sell |
1,086
-258
| -19% | -$9.67K | ﹤0.01% | 3185 |
|
|
2017
Q2 | $49.8K | Buy |
1,344
+665
| +98% | +$29.4K | ﹤0.01% | 3198 |
|
|
2017
Q1 | $36.8K | Sell |
679
-6,751
| -91% | -$352K | ﹤0.01% | 2846 |
|
|
2016
Q4 | $395K | Sell |
7,430
-2,376
| -24% | -$135K | ﹤0.01% | 1814 |
|
|
2016
Q3 | $594K | Buy |
9,806
+2,324
| +31% | +$145K | ﹤0.01% | 1136 |
|
|
2016
Q2 | $493K | Sell |
7,482
-1,522
| -17% | -$96.6K | ﹤0.01% | 1520 |
|
|
2016
Q1 | $511K | Buy |
9,004
+368
| +4% | +$41.4K | ﹤0.01% | 1198 |
|
|
2015
Q4 | $2.03M | Buy |
8,636
+584
| +7% | +$127K | ﹤0.01% | 905 |
|
|
2015
Q3 | $1.27M | Buy |
8,052
+4,130
| +105% | +$1.17M | ﹤0.01% | 974 |
|
|
2015
Q2 | $1.48M | Buy |
3,922
+2,699
| +221% | +$1.07M | ﹤0.01% | 997 |
|
|
2015
Q1 | $511K | Sell |
1,223
-1,409
| -54% | -$504K | ﹤0.01% | 1306 |
|
|
2014
Q4 | $721K | Sell |
2,632
-5,200
| -66% | -$1.29M | ﹤0.01% | 1038 |
|
|
2014
Q3 | $1.52M | Buy |
7,832
+5,138
| +191% | +$1.12M | ﹤0.01% | 1114 |
|
|
2014
Q2 | $660K | Buy |
2,694
+1,854
| +221% | +$419K | ﹤0.01% | 1367 |
|
|
2014
Q1 | $189K | Buy |
840
+764
| +1,005% | +$293K | ﹤0.01% | 1813 |
|
|
2013
Q4 | $27.6K | Sell |
76
-1,415
| -95% | -$545K | ﹤0.01% | 2111 |
|
|
2013
Q3 | $792K | Sell |
1,491
-387
| -21% | -$133K | ﹤0.01% | 1256 |
|
|
2013
Q2 | $440K | Buy |
+1,878
| New | +$370K | ﹤0.01% | 1663 |
|
Other funds holding CLDX
DTC
LGM
EP
CC
BNP Paribas Financial Markets's CLDX Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Celldex Therapeutics (CLDX) stake by 82% in Q2 2026, selling an estimated $4.67M and leaving 31,191 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3214.
BNP Paribas Financial Markets first reported a position in CLDX in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.26M in Q4 2025. 234 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.
- BNP Paribas Financial Markets held 31,191 shares of Celldex Therapeutics worth $1.16M as of Q2 2026.
- BNP Paribas Financial Markets sold 144,597 Celldex Therapeutics shares in Q2 2026, an estimated $4.67M.
- Celldex Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3214 holding.
- BNP Paribas Financial Markets first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 52 quarters since.
- BNP Paribas Financial Markets's Celldex Therapeutics position peaked at $6.26M in Q4 2025.
- 234 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.